Partnership for Safe Medicines petitions FDA to block compounding of unapproved peptides
The Partnership for Safe Medicines, a public-health nonprofit coalition, filed a formal citizen petition with the FDA on October 21, 2026, asking the agency to block compounding of unapproved and uncharacterized peptides by any route and to set aside a July advisory committee vote the group says was compromised by conflicts of interest. FDA must respond within 180 days; the petition is a request, not an agency decision.
The Partnership for Safe Medicines (PSM) announced on October 21, 2026 that it has filed a citizen petition with the U.S. Food and Drug Administration urging the agency to block compounding of unapproved and uncharacterized peptides by any route, and to disregard the July meeting of the Pharmacy Compounding Advisory Committee (PCAC) as a basis for future rulemaking. A citizen petition is a formal mechanism under 21 C.F.R. § 10.30 that places arguments into the official administrative record; FDA is required to respond within 180 days. The filing changes no existing rule, and the petition itself is publicly available on FDA's docket at regulations.gov.
According to PSM, at the July PCAC meeting FDA's own scientists recommended against bulk compounding of all seven substances under consideration - BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon - while the committee voted in favor of allowing six of the seven. PSM argues the vote should be set aside because, in its account, newly appointed committee members held financial ties to the peptide industry in violation of the Federal Advisory Committee Act and the Ethics in Government Act. These are the petitioner's allegations; FDA has not endorsed them and has not yet responded to the petition.
“We are deeply concerned that legitimizing untested and poorly defined substances knowingly puts Americans at risk,” said Shabbir Imber Safdar, PSM's executive director, adding that FDA scientists “found no adequate characterization, extremely limited safety data, and no meaningful human evidence” for the substances reviewed.
The petition also describes an internal investigation in which PSM's research team purchased unauthorized peptides labeled from four state-licensed 503A compounding pharmacies in Texas and Pennsylvania, with the products ordered from and delivered to California. According to PSM, three of the four pharmacies hold no known California licenses, the fourth lacks a non-resident sterile compounding license, and all of the products arrived with syringes and injection instructions rather than “research use only” labeling.
The petition lands while FDA's own “Interim Access Policy for Compounding Using Certain Peptides” sits under White House budget-office review, leaving the regulatory direction for compounded peptides actively contested from multiple directions. For patients, nothing changes today: unapproved peptides sold outside licensed channels remain outside the quality controls of approved medicines, and FDA's formal response to the petition - due within 180 days of filing - will be the next dated milestone. Peptide Health Directory will report the agency's response when it is posted.